Navigation Links
Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
Date:11/13/2008

Long-Acting hGH Analogue Requires Only Weekly Dosing

SAN DIEGO, Nov. 13 /PRNewswire/ -- Ambrx Inc. today announced Phase I/II clinical trial data demonstrating that ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, normalized insulin-like growth factor I (IGF-I) levels while delivering an acceptable safety and tolerability profile in adults with Growth Hormone deficiency. The results of this trial support further evaluation of ARX201 as an option for the treatment of adult growth hormone deficiency (AGHD).

In the 26-week study, normal levels of IGF-I, a marker for hGH activity, were maintained with injections given once a week. The clinical trial results were presented today at the International Congress of Endocrinology Conference in Rio de Janeiro by Andrew Hoffman, M.D., Professor of Medicine and Vice Chair for Academic Affairs at Stanford University.

"We are very excited by these promising clinical results and are hopeful that ARX201 will provide a better treatment option for patients with AGHD that currently require daily injections," said Stephen Kaldor, Ph.D., president and CEO of Ambrx. "Additionally, this study provides proof of concept that protein analogues made using Ambrx's ReCODE(TM) technology have retained potency with an improved pharmacological profile over conventional protein therapeutics. This opens the door for Ambrx to create more effective protein-based therapies across a broad range of treatment classes."

The Phase I/II study of ARX201, analyzed 22 AGHD patients who had not received hGH replacement therapy in the six months prior to the trial. ARX201 was administered by subcutaneous injection on a weekly basis for 26 weeks. IGF-I levels increased to normal values and remained such throughout the course of the trial. Patients experienced a mean truncal fat loss of 5.6 percent and a mean total body fat loss of 1.3 percent. The mean increase in
'/>"/>

SOURCE Ambrx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Caris Life Sciences ® , a leading ... precision medicine, today announced the presentation of data ... of Caris Molecular Intelligence ® , the company,s ... identify targeted treatment options for patients with rare ... results of which are to be presented in ...
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, http://www.seoulsemicon.com ), ... announced that it will increase the global automotive ... and high reliable LED product line-up for the ... developed efficient and reliable LED packages for the ... headlamps to global auto makers. Seoul Semiconductor’s 14 ...
(Date:5/28/2015)... 28, 2015  Quest Diagnostics Incorporated (NYSE: DGX ... announced that it is scheduled to speak at the ... Steve Rusckowski , the company,s President and CEO, will ...  The presentation is scheduled for Tuesday, June 2, 2015 ... will be webcast live during the conference and will ...
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) ... report "Cell Therapy - Technologies, Markets and ... report describes and evaluates cell therapy technologies and ... important role in the practice of medicine. Hematopoietic ... bone marrow transplants. Role of cells in drug ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... July 11, 2011 MRIGlobal, an internationally recognized ... the U.S. and overseas, has appointed Richard A. Winegar, ... http://photos.prnewswire.com/prnh/20110711/DC32923 ) Dr. Winegar is ... in radiation biology and genetic toxicology.  As Principal Advisor ...
... WORCESTER, Mass. and TORONTO, July 11, 2011 ... announced today the publication of studies conducted at ... Ii-Key technology.  Antigen Express, Inc., the Company,s wholly-owned ... development of self-potentiating immunotherapeutic vaccines for cancer.  AE37, ...
... York, NY July 10, 2011 Researchers at ... them to engineer the index of refraction and fully ... possible for light (electromagnetic waves) to propagate from point ... through the artificial medium as if the medium is ...
Cached Biology Technology:MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science 2Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 2Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 3Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 4Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 5Light propagation controlled in photonic chips -- major breakthrough in telecommunications field 2
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... FP7 funded project IMPRESSIONS (Impacts and Risks from High-End Scenarios: ... from 13 to 15 January 2014 in Oxford, United Kingdom. ... 18 countries will join forces to answer one of the ... future of humankind and nature if climate continues to change ...
... of great current interest as chemical sensors, in ... David G. Cahill, a Willett Professor and head ... at the University of Illinois at Urbana-Champaign. "Applications ... of light at a different wavelength than the ...
... retina can be bombarded by reactive oxygen species in diabetes, ... ones and ruin vision. Now researchers have learned that ... marrow as well as the retinal cells themselves to cause ... players to signal the next event that causes the damage," ...
Cached Biology News:IMPRESSIONS: Advancing understanding of the consequences of high-end climate change 2IMPRESSIONS: Advancing understanding of the consequences of high-end climate change 3Understanding secondary light emission by plasmonic nanostructures may improve medical imaging 22 players produce destructive cascade of diabetic retinopathy 2
... Start Taq Monoclonal Antibody ... the onset of thermal ... and primer-dimer formation. When ... the antibody is quickly ...
... Human Pathogenic Viruses The ... (NCPV) preserves well characterised, authenticated ... secure facility, and NCPV is ... or nucleic acids derived from ...
... 5 Fluorescein 6-Fam, Hex, ... 3 Fluorescein Tamra Black Hole ... 6-Fam, Hex, Tet Tamra, Joe ... Health Research Institute, New York Double labelled ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: